Clinical Trial Update: Sirolimus for Improving Social Abilities in People With PTEN Germline Mutations [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 clinical trial evaluating sirolimus for improving social abilities in people with PTEN germline mutations has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pten Hamartoma Tumor Syndrome

Drugs mentioned

• Sirolimus (Sirolimus)

Snippet

Sponsor: Stanford University | Conditions: PTEN Gene Mutation, PTEN Hamartoma Tumor Syndrome | Phase 1, Phase 2 | Status: WITHDRAWN